Natco appeals against US Copaxone ruling
This article was originally published in Scrip
Executive Summary
Natco Pharma has appealed against a US court ruling in a case concerning its generic version of Teva Pharmaceutical Industries' multiple sclerosis drug, Copaxone (glatiramer acetate), even as some analysts believe that a generic launch ahead of the expiry of the process patent for the product could still offer significant gains.